Business

Exclusive: ValueAct CEO says Valeant does not need to buy Allergan

ValueAct Capital, a top shareholder in Valeant Pharmaceuticals International Inc , supports the company's standalone plan and does not believe the Canadian drugmaker has to buy Allergan Inc ,...

Archive